Fusion Glycoprotein Vaccine for Human Metapneumovirus

Human metapneumovirus (hMPV), a negative, single-stranded RNA virus, accounts for approximately 5-15% of infant respiratory tract infections and poses a severe risk of disease and hospitalization in both the elderly and the immunocompromised. Investigators at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID) have generated an hMPV fusion glycoprotein ( “F protein”) stabilized in a prefusion conformation.Stabilizing this prefusion conformation of the F protein reveals an immunodominant site which makes it an ideal vaccine immunogen. The prefusion stabilized F protein immunogen can be delivered as either an isolated homotrimer or trimers displayed on a nanoparticle. These immunogens elicit broad and potent hMPV-neutralizing antibodies.This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404.IC: NIAIDNIH Ref. No.: E-260-2014-0Advantages: No human metapneumovirus vaccine is currently availableApplications: Vaccine for prevention of human metapneumovirus infectionProvider Technology ID: 3342Updated On: Oct 29, 2018Date Published: Monday, October 29, 2018Provider Classifications: Publications: Patent Application: 62/096,744PCT/IB2015/05999115/539,64015831073.0Patent Authority: USPCTUSEPLicensing Contacts: Lead Inventor: Inventor IC: NIAIDNIAIDNIAIDNIAIDNIAIDNIAIDNIAIDInstitute for Research...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research